Press Release

Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases 

by
Aspen Neuroscience Logo

Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life  

This Personalized Autologous Cell Therapy Aims to Replace and Restore the Damaged Neural Circuitry in Parkinson’s Patients that Underpins Everyday Movement and Function, Without the Need for Immune Suppression 

SAN DIEGO, Mar. 18, 2026 /PRNewswire/ — Aspen Neuroscience, a clinical-stage regenerative medicine company developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need, today announced data from its ongoing Phase 1/2a ASPIRO* clinical trial in a late‑breaking oral presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases, taking place March 17–21, 2026 in Copenhagen, Denmark.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson’s Disease

by
Aspen Neuroscience Logo

Approved for Use By both the World Health Organization’s International Nonproprietary Names (WHO-INN) and the American Medical Association’s United States Adopted Names (AMA-USAN) Council

SAN DIEGO, Mar. 12, 2026 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced that the World Health Organization (WHO) has published Sasineprocel as the International Nonproprietary Name (INN) for Aspen’s investigational therapy ANPD001, with clearance also from the American Medical Association’s United States Adopted Names (AMA-USAN) Council, pending publication.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients

by
Aspen Neuroscience Logo

Facility Enters Qualification to Support Late‑Stage Pivotal Manufacturing and Commercial Readiness 

SAN DIEGO, Jan. 8, 2026 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced completion of Cohort Three* dosing in the company’s ASPIRO Phase 1/2a trial of ANPD001, a personalized dopaminergic neuronal precursor cell (DANPC) therapy for moderate to advanced Parkinson’s disease (PD).

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness 

by
Aspen Neuroscience Logo

SAN DIEGO, Jan.7, 2025 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced two executive leadership appointments: Revati Shreeniwas, M.D., FCCP has joined Aspen as Chief Medical Officer (CMO), and Lisa Johnson‑Pratt, M.D., who has been leading Aspen’s therapeutic program strategy for ANPD001, will transition into the role of Chief Commercial … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

by
Aspen Neuroscience Logo

SAN DIEGO, Nov. 20, 2025 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen’s lead program, ANPD001, for moderate to advanced Parkinson’s disease. The Series C round was co-led … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease

by
Aspen Neuroscience Logo

SAN DIEGO, September 25, 2025 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the initiation of Cohort 3* in its ASPIRO Phase 1/2a clinical trial of ANPD001, the company’s personalized dopaminergic neuronal precursor cell (DANPC) therapy for moderate to advanced Parkinson’s disease (PD). This milestone marks the first administration of Aspen’s commercial … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting

by
Andrés Bratt Leal

Presentation of Data from Clinical Trial of Aspen’s Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson’s Disease

SAN DIEGO, June 9, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. announced its participation in “Illuminating the Future,” the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in Hong Kong June 11-14.

Aspen Co-founder and Senior Vice President, Research and Development, Andrés Bratt-Leal, PhD will deliver a presentation, Safety, tolerability, and efficacy of transplanted autologous iPSC-derived dopaminergic precursors in moderate to advanced Parkinson’s Disease.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

by
Xiaokui Zhang, PhD

Presentation Covers Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease

SAN DIEGO, May 14, 2025 /PRNewswire/ — Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held this week May 13-17, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The annual meeting, the largest gathering of cell and gene therapy professionals, hosts a global audience of attendees from academia, the biotechnology and pharmaceutical industries, government, and non-profit patient foundations.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

by
step 234 edited

SAN DIEGO and NEW YORK, May 7, 2025 /PRNewswire/ — Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) therapy being studied in patients with moderate to advanced Parkinson’s Disease (PD). After recent publication in Parkinsonism and Related Disorders, detailed 6-month data on … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

by
Xiaokui Zhang, Ph.D

Presentations Cover Automated Manufacturing of Aspen’s Autologous iPSC-derived Neuron Replacement Therapy for Parkinson’s Disease.

SAN DIEGO and NEW ORLEANS, May 7, 2025 /PRNewswire/ — Aspen Neuroscience scientists, led by Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting, held this week May 7-10 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo Reverse Horizontal RGB

Aspen Neuroscience leverages stem cell biology and advanced genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2026 Aspen Neuroscience - All Rights Reserved